Review



mrna expression of arpc5  (Human Protein Atlas)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Human Protein Atlas mrna expression of arpc5
    The expression levels of APRC5 in different cancers, normal tissues, and cells. (A) The differential expression of <t>ARPC5</t> in pan-cancer tissues from TCGA datasets. (B) The differential expression of ARPC5 in pan-cancer tissues based on TCGA and GTEx datasets. (C) ARPC5 expression in paired cancer tissues and adjacent normal tissues from TCGA datasets. (D) The mRNA expression levels of ARPC5 in different normal tissues from HPA database. (E) The mRNA expression of ARPC5 in cancer cell lines from HPA database. (F) ARPC5 mRNA expression in different single cell types from HPA database. ns: no significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Mrna Expression Of Arpc5, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mrna+expression+of+arpc5/mrna+expression+of+arpc5/pmc09485570-168-4-18
    Average 90 stars, based on 1 article reviews
    mrna expression of arpc5 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma"

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2022.944898

    The expression levels of APRC5 in different cancers, normal tissues, and cells. (A) The differential expression of ARPC5 in pan-cancer tissues from TCGA datasets. (B) The differential expression of ARPC5 in pan-cancer tissues based on TCGA and GTEx datasets. (C) ARPC5 expression in paired cancer tissues and adjacent normal tissues from TCGA datasets. (D) The mRNA expression levels of ARPC5 in different normal tissues from HPA database. (E) The mRNA expression of ARPC5 in cancer cell lines from HPA database. (F) ARPC5 mRNA expression in different single cell types from HPA database. ns: no significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Figure Legend Snippet: The expression levels of APRC5 in different cancers, normal tissues, and cells. (A) The differential expression of ARPC5 in pan-cancer tissues from TCGA datasets. (B) The differential expression of ARPC5 in pan-cancer tissues based on TCGA and GTEx datasets. (C) ARPC5 expression in paired cancer tissues and adjacent normal tissues from TCGA datasets. (D) The mRNA expression levels of ARPC5 in different normal tissues from HPA database. (E) The mRNA expression of ARPC5 in cancer cell lines from HPA database. (F) ARPC5 mRNA expression in different single cell types from HPA database. ns: no significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Techniques Used: Expressing, Quantitative Proteomics

    Genetic alteration of ARPC5 in pan-cancer. (A) Mutation type and mutation frequency of ARPC5 obtained from the cBioPortal website. (B) The expression levels of ARPC5 in various CNV status of pan-cancer, CNV, copy number variations; *p < 0 . 0 5 ; * *p < 0.01; ****p < 0.0001.
    Figure Legend Snippet: Genetic alteration of ARPC5 in pan-cancer. (A) Mutation type and mutation frequency of ARPC5 obtained from the cBioPortal website. (B) The expression levels of ARPC5 in various CNV status of pan-cancer, CNV, copy number variations; *p < 0 . 0 5 ; * *p < 0.01; ****p < 0.0001.

    Techniques Used: Mutagenesis, Expressing

    Prognosis analyses of ARPC5 in pan-cancer based on univariate Cox regression method. (A) The correlation between ARPC5 expression and OS. (B) The correlation between ARPC5 expression and PFI. (C) The correlation between ARPC5 expression and DSS. OS: overall survival; PFI: progression-free interval; DSS: disease-specific survival.
    Figure Legend Snippet: Prognosis analyses of ARPC5 in pan-cancer based on univariate Cox regression method. (A) The correlation between ARPC5 expression and OS. (B) The correlation between ARPC5 expression and PFI. (C) The correlation between ARPC5 expression and DSS. OS: overall survival; PFI: progression-free interval; DSS: disease-specific survival.

    Techniques Used: Expressing

    ARPC5 expression significantly correlated with OS based on Kaplan–Meier analysis. (A) The correlation in ESCA. (B) The correlation in HNSC. (C) The correlation in KIRC. (D) The correlation in KIRP. (E) The correlation in LIHC. (F) The correlation in LGG. (G) The correlation in OV. (H) The correlation in SKCM. The optimal cutoff of ARPC5 expression were used to divide patients into high- and low-expression groups.
    Figure Legend Snippet: ARPC5 expression significantly correlated with OS based on Kaplan–Meier analysis. (A) The correlation in ESCA. (B) The correlation in HNSC. (C) The correlation in KIRC. (D) The correlation in KIRP. (E) The correlation in LIHC. (F) The correlation in LGG. (G) The correlation in OV. (H) The correlation in SKCM. The optimal cutoff of ARPC5 expression were used to divide patients into high- and low-expression groups.

    Techniques Used: Expressing

    The correlation between ARPC5 expression and clinical stage, histologic grade, and tumor molecular subtypes in various cancers based on Spearman’s correlation analysis (the correlation with p < 0.05 were displayed). (A) The correlation between ARPC5 expression and clinical stage in pan-cancer. (B–C) The expression levels of ARPC5 in different clinical stages of KIRC (B) and KIRP (C) . (D) The correlation between ARPC2 expression and histologic grade in pan-cancer. (E–H) The expression levels of ARPC5 in different histologic grades of KIRC (E) , LGG (F) , LIHC (G) , and UCEC (H) . (I–R) The correlation between ARPC5 expression and molecular subtypes in ACC (I) , BRCA (J) , LGG (K) , HNSC (L) , KIRP (M) , OV (N) , LUSC (O) , PCPG (P) , STAD (Q) , UCEC (R) . rho; rank coefficient of Spearman. Pv; p -value. NS, no significance.
    Figure Legend Snippet: The correlation between ARPC5 expression and clinical stage, histologic grade, and tumor molecular subtypes in various cancers based on Spearman’s correlation analysis (the correlation with p < 0.05 were displayed). (A) The correlation between ARPC5 expression and clinical stage in pan-cancer. (B–C) The expression levels of ARPC5 in different clinical stages of KIRC (B) and KIRP (C) . (D) The correlation between ARPC2 expression and histologic grade in pan-cancer. (E–H) The expression levels of ARPC5 in different histologic grades of KIRC (E) , LGG (F) , LIHC (G) , and UCEC (H) . (I–R) The correlation between ARPC5 expression and molecular subtypes in ACC (I) , BRCA (J) , LGG (K) , HNSC (L) , KIRP (M) , OV (N) , LUSC (O) , PCPG (P) , STAD (Q) , UCEC (R) . rho; rank coefficient of Spearman. Pv; p -value. NS, no significance.

    Techniques Used: Expressing

    The correlation between ARPC5 expression and immune scores and stromal scores of tumor microenvironments in pan-cancer.
    Figure Legend Snippet: The correlation between ARPC5 expression and immune scores and stromal scores of tumor microenvironments in pan-cancer.

    Techniques Used: Expressing

    The correlation between ARPC5 and immune infiltration cells in pan-cancer based on TIMER algorithm. (A) Heatmap displayed the correlation between ARPC5 expression and the proportions of B cell, CD4 + T cell, CD8 + T cell, neutrophil, macrophage, and DC cell. (B) The top five cancer types (including KIRC, LGG, PRAD, THCA, and THYM) with most significant correlation between ARPC5 and immune infiltration cells were displayed with scatterplots. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Figure Legend Snippet: The correlation between ARPC5 and immune infiltration cells in pan-cancer based on TIMER algorithm. (A) Heatmap displayed the correlation between ARPC5 expression and the proportions of B cell, CD4 + T cell, CD8 + T cell, neutrophil, macrophage, and DC cell. (B) The top five cancer types (including KIRC, LGG, PRAD, THCA, and THYM) with most significant correlation between ARPC5 and immune infiltration cells were displayed with scatterplots. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Techniques Used: Expressing

    The correlation between ARPC5 expression and immune subtypes in pan-cancer using TISIDB. The cancers with significant correlation were displayed. (A) In BLCA. (B) In BRCA. (C) In CESC. (D) In KICH. (E) In KIRC. (F) In LGG. (G) In LIHC. (H) In LUAD. (I) In PAAD. (J) In OV. (K) PCPG. (L) PRAD. (M) In READ. ( N) In SARC. (O) In SKCM. (P) In STAD. (Q) In TGCT. (R) In THCA. (S) In UCS. (T) In UCEC. Pv; p -value. C1, wound healing; C2, IFN-gamma dominant; C3, inflammatory; C4, lymphocyte depleted; C5, immunologically quiet; C6, TGF-b dominant.
    Figure Legend Snippet: The correlation between ARPC5 expression and immune subtypes in pan-cancer using TISIDB. The cancers with significant correlation were displayed. (A) In BLCA. (B) In BRCA. (C) In CESC. (D) In KICH. (E) In KIRC. (F) In LGG. (G) In LIHC. (H) In LUAD. (I) In PAAD. (J) In OV. (K) PCPG. (L) PRAD. (M) In READ. ( N) In SARC. (O) In SKCM. (P) In STAD. (Q) In TGCT. (R) In THCA. (S) In UCS. (T) In UCEC. Pv; p -value. C1, wound healing; C2, IFN-gamma dominant; C3, inflammatory; C4, lymphocyte depleted; C5, immunologically quiet; C6, TGF-b dominant.

    Techniques Used: Expressing

    The relationship between ARPC5 and immune-checkmate inhibitors biomarkers in pan-cancer. (A) The heatmap showing the co-expression relationship between ARPC5 and 47 immune checkpoint–related genes. (B) Radar plot showing the relationship between ARPC5 and tumor mutation burden (TMB). (C) Radar plot showing the correlation of ARPC5 with microsatellite instability (MSI). (D) Radar plot showing the correlation of ARPC5 with neoantigens. The number in radar plot represents Spearman’s correlation coefficient. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Figure Legend Snippet: The relationship between ARPC5 and immune-checkmate inhibitors biomarkers in pan-cancer. (A) The heatmap showing the co-expression relationship between ARPC5 and 47 immune checkpoint–related genes. (B) Radar plot showing the relationship between ARPC5 and tumor mutation burden (TMB). (C) Radar plot showing the correlation of ARPC5 with microsatellite instability (MSI). (D) Radar plot showing the correlation of ARPC5 with neoantigens. The number in radar plot represents Spearman’s correlation coefficient. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Techniques Used: Expressing, Mutagenesis, Immunopeptidomics

    Correlation analysis between ARPC5 expression and RNA modification-related genes, DNA methyltransferases, and tumor stemness score in 33 cancer types. (A) Co-expression of ARPC5 with m1A-related genes. (B) Co-expression of ARPC5 with m5C-related genes. (C) Co-expression of ARPC5 with m6A-related genes. (D) Co-expression of ARPC5 with DNA methyltransferases. (E) The correlation between ARPC5 expression and Tumor Stemness score (DNAss). (F) The correlation between ARPC5 expression and Tumor Stemness score (RNAss). * p < 0.05; ** p < 0.01; *** p < 0.001.
    Figure Legend Snippet: Correlation analysis between ARPC5 expression and RNA modification-related genes, DNA methyltransferases, and tumor stemness score in 33 cancer types. (A) Co-expression of ARPC5 with m1A-related genes. (B) Co-expression of ARPC5 with m5C-related genes. (C) Co-expression of ARPC5 with m6A-related genes. (D) Co-expression of ARPC5 with DNA methyltransferases. (E) The correlation between ARPC5 expression and Tumor Stemness score (DNAss). (F) The correlation between ARPC5 expression and Tumor Stemness score (RNAss). * p < 0.05; ** p < 0.01; *** p < 0.001.

    Techniques Used: Expressing, RNA modification

    ARPC5 is upregulated in HCC cells and primary HCC tissues. (A) qPCR analysis of ARPC5 mRNA expression in four HCC cell lines (MHCC97-H, Huh7, HCC-LM3, and HepG2) and normal liver cell line (LO2). GAPDH was used as an internal control error bars represent M ± SEM (triplicate experiments). (B, C) The protein expression of ARPC5 was detected in four HCC cell lines and normal liver cell line with Western blot analysis. Error bars represent M ± SD of triplicate measurements. (D) The mRNA expression of ARPC5 in 40 pairs HCC tissues and adjacent para-carcinoma tissues was evaluated using qPCR. (E) Western blot analysis of ARPC5 protein expression in 10 paired HCC tissues and adjacent normal tissues. The number presented the relative protein expression levels of ARPC5. (F) Representative images of ARPC5 immunohistochemical staining analysis in the HCC tissue and adjacent normal liver tissue, original magnifications: ×40 and ×200. Scale bars, 50 μm. (G) Quantitative analysis of ARPC5 expression in HCC tissues based on mean optical density of immunohistochemical staining. Error bars represent the M ± SD of multiple tissues. (H) Kaplan–Meier curves showed that higher expression of ARPC5 was associated with poor DFS in HCC patients. * p < 0.05; ** p < 0.01; *** p < 0.001. ns, no significance.
    Figure Legend Snippet: ARPC5 is upregulated in HCC cells and primary HCC tissues. (A) qPCR analysis of ARPC5 mRNA expression in four HCC cell lines (MHCC97-H, Huh7, HCC-LM3, and HepG2) and normal liver cell line (LO2). GAPDH was used as an internal control error bars represent M ± SEM (triplicate experiments). (B, C) The protein expression of ARPC5 was detected in four HCC cell lines and normal liver cell line with Western blot analysis. Error bars represent M ± SD of triplicate measurements. (D) The mRNA expression of ARPC5 in 40 pairs HCC tissues and adjacent para-carcinoma tissues was evaluated using qPCR. (E) Western blot analysis of ARPC5 protein expression in 10 paired HCC tissues and adjacent normal tissues. The number presented the relative protein expression levels of ARPC5. (F) Representative images of ARPC5 immunohistochemical staining analysis in the HCC tissue and adjacent normal liver tissue, original magnifications: ×40 and ×200. Scale bars, 50 μm. (G) Quantitative analysis of ARPC5 expression in HCC tissues based on mean optical density of immunohistochemical staining. Error bars represent the M ± SD of multiple tissues. (H) Kaplan–Meier curves showed that higher expression of ARPC5 was associated with poor DFS in HCC patients. * p < 0.05; ** p < 0.01; *** p < 0.001. ns, no significance.

    Techniques Used: Expressing, Control, Western Blot, Immunohistochemical staining, Staining

    Silencing of ARPC5 inhibits cell proliferation and promotes cell apoptosis of HCC. (A) The knockdown efficiency of siRNA–ARPC5 was examined in HCC-LM3 and MHCC97-H cells with qPCR. (B) The knockdown efficiency of siRNA-ARPC5 was examined in HCC-LM3 and MHCC97-H cells with Western blot. The number presented as relative protein expression levels of ARPC5. ( C–D ) EdU assays for HCC-LM3 and MHCC 97-H were performed to evaluate cell proliferation ability after transfecting siRNA-ARPC5#1. Representative images (C) and the number of proliferative cells were calculated (D) ; original magnification, ×200. (E–F) Cellular growth curves were evaluated by CCK-8 assays in HCC-LM3 and MHCC97-H cells. (G – H) Flow cytometry was applied to test the apoptosis of HCC cells transfected with si-ARPC5 #1 in HCC-LM3 and MHCC 97-H cells. All data are presented as the M ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001. ns, no significance.
    Figure Legend Snippet: Silencing of ARPC5 inhibits cell proliferation and promotes cell apoptosis of HCC. (A) The knockdown efficiency of siRNA–ARPC5 was examined in HCC-LM3 and MHCC97-H cells with qPCR. (B) The knockdown efficiency of siRNA-ARPC5 was examined in HCC-LM3 and MHCC97-H cells with Western blot. The number presented as relative protein expression levels of ARPC5. ( C–D ) EdU assays for HCC-LM3 and MHCC 97-H were performed to evaluate cell proliferation ability after transfecting siRNA-ARPC5#1. Representative images (C) and the number of proliferative cells were calculated (D) ; original magnification, ×200. (E–F) Cellular growth curves were evaluated by CCK-8 assays in HCC-LM3 and MHCC97-H cells. (G – H) Flow cytometry was applied to test the apoptosis of HCC cells transfected with si-ARPC5 #1 in HCC-LM3 and MHCC 97-H cells. All data are presented as the M ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001. ns, no significance.

    Techniques Used: Knockdown, Western Blot, Expressing, CCK-8 Assay, Flow Cytometry, Transfection

    Role of ARPC5 inhibition on migration, invasion, and epithelial–mesenchymal transition (EMT) of HCC cells. (A–D) Migration ability was assessed by scratch wound healing assay, representative images (A, B) were shown (original magnification, ×200; scale bars, 50 µm), and wound healing areas were calculated (C, D) . (E , F) Transwell assay was applied to examine the invasion ability, representative images (F) were shown (original magnification, ×200; scale bars, 50 µm), and the histogram showed the number of invasion cells (E) . (G) Western blot showed the changes of EMT proteins in HCC-LM3 and MHCC97-H cells transfected with si-ARPC5#1. *p < 0.05; **p < 0.01; ***p < 0.001.
    Figure Legend Snippet: Role of ARPC5 inhibition on migration, invasion, and epithelial–mesenchymal transition (EMT) of HCC cells. (A–D) Migration ability was assessed by scratch wound healing assay, representative images (A, B) were shown (original magnification, ×200; scale bars, 50 µm), and wound healing areas were calculated (C, D) . (E , F) Transwell assay was applied to examine the invasion ability, representative images (F) were shown (original magnification, ×200; scale bars, 50 µm), and the histogram showed the number of invasion cells (E) . (G) Western blot showed the changes of EMT proteins in HCC-LM3 and MHCC97-H cells transfected with si-ARPC5#1. *p < 0.05; **p < 0.01; ***p < 0.001.

    Techniques Used: Inhibition, Migration, Wound Healing Assay, Transwell Assay, Western Blot, Transfection


    Figure Legend Snippet:

    Techniques Used: Expressing, Mutagenesis, Real-time Polymerase Chain Reaction, Small Interfering RNA

    Related Articles

    Expressing:

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma
    Article Snippet: .. Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ). .. The web-accessible database cBioPortal ( https://www.cbioportal.org/ ) was utilized to analyze the gene mutation characteristics of ARPC5, including the alteration frequency, mutation type, and copy number alteration in pan-cancer.

    Single Cell:

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma
    Article Snippet: .. Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ). .. The web-accessible database cBioPortal ( https://www.cbioportal.org/ ) was utilized to analyze the gene mutation characteristics of ARPC5, including the alteration frequency, mutation type, and copy number alteration in pan-cancer.



    Similar Products

    mrna expression of arpc5  (Human Protein Atlas)
    90
    Human Protein Atlas mrna expression of arpc5
    The expression levels of APRC5 in different cancers, normal tissues, and cells. (A) The differential expression of <t>ARPC5</t> in pan-cancer tissues from TCGA datasets. (B) The differential expression of ARPC5 in pan-cancer tissues based on TCGA and GTEx datasets. (C) ARPC5 expression in paired cancer tissues and adjacent normal tissues from TCGA datasets. (D) The mRNA expression levels of ARPC5 in different normal tissues from HPA database. (E) The mRNA expression of ARPC5 in cancer cell lines from HPA database. (F) ARPC5 mRNA expression in different single cell types from HPA database. ns: no significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Mrna Expression Of Arpc5, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mrna+expression+of+arpc5/mrna+expression+of+arpc5/pmc09485570-168-4-18
    Average 90 stars, based on 1 article reviews
    mrna expression of arpc5 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mrna expression levels of arpc5  (SAS institute)
    90
    SAS institute mrna expression levels of arpc5
    The expression levels of APRC5 in different cancers, normal tissues, and cells. (A) The differential expression of <t>ARPC5</t> in pan-cancer tissues from TCGA datasets. (B) The differential expression of ARPC5 in pan-cancer tissues based on TCGA and GTEx datasets. (C) ARPC5 expression in paired cancer tissues and adjacent normal tissues from TCGA datasets. (D) The mRNA expression levels of ARPC5 in different normal tissues from HPA database. (E) The mRNA expression of ARPC5 in cancer cell lines from HPA database. (F) ARPC5 mRNA expression in different single cell types from HPA database. ns: no significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Mrna Expression Levels Of Arpc5, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mrna+expression+of+arpc5/mrna+expression+levels+of+arpc5/pm22378351-119-5-7
    Average 90 stars, based on 1 article reviews
    mrna expression levels of arpc5 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The expression levels of APRC5 in different cancers, normal tissues, and cells. (A) The differential expression of ARPC5 in pan-cancer tissues from TCGA datasets. (B) The differential expression of ARPC5 in pan-cancer tissues based on TCGA and GTEx datasets. (C) ARPC5 expression in paired cancer tissues and adjacent normal tissues from TCGA datasets. (D) The mRNA expression levels of ARPC5 in different normal tissues from HPA database. (E) The mRNA expression of ARPC5 in cancer cell lines from HPA database. (F) ARPC5 mRNA expression in different single cell types from HPA database. ns: no significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: The expression levels of APRC5 in different cancers, normal tissues, and cells. (A) The differential expression of ARPC5 in pan-cancer tissues from TCGA datasets. (B) The differential expression of ARPC5 in pan-cancer tissues based on TCGA and GTEx datasets. (C) ARPC5 expression in paired cancer tissues and adjacent normal tissues from TCGA datasets. (D) The mRNA expression levels of ARPC5 in different normal tissues from HPA database. (E) The mRNA expression of ARPC5 in cancer cell lines from HPA database. (F) ARPC5 mRNA expression in different single cell types from HPA database. ns: no significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing, Quantitative Proteomics

    Genetic alteration of ARPC5 in pan-cancer. (A) Mutation type and mutation frequency of ARPC5 obtained from the cBioPortal website. (B) The expression levels of ARPC5 in various CNV status of pan-cancer, CNV, copy number variations; *p < 0 . 0 5 ; * *p < 0.01; ****p < 0.0001.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: Genetic alteration of ARPC5 in pan-cancer. (A) Mutation type and mutation frequency of ARPC5 obtained from the cBioPortal website. (B) The expression levels of ARPC5 in various CNV status of pan-cancer, CNV, copy number variations; *p < 0 . 0 5 ; * *p < 0.01; ****p < 0.0001.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Mutagenesis, Expressing

    Prognosis analyses of ARPC5 in pan-cancer based on univariate Cox regression method. (A) The correlation between ARPC5 expression and OS. (B) The correlation between ARPC5 expression and PFI. (C) The correlation between ARPC5 expression and DSS. OS: overall survival; PFI: progression-free interval; DSS: disease-specific survival.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: Prognosis analyses of ARPC5 in pan-cancer based on univariate Cox regression method. (A) The correlation between ARPC5 expression and OS. (B) The correlation between ARPC5 expression and PFI. (C) The correlation between ARPC5 expression and DSS. OS: overall survival; PFI: progression-free interval; DSS: disease-specific survival.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing

    ARPC5 expression significantly correlated with OS based on Kaplan–Meier analysis. (A) The correlation in ESCA. (B) The correlation in HNSC. (C) The correlation in KIRC. (D) The correlation in KIRP. (E) The correlation in LIHC. (F) The correlation in LGG. (G) The correlation in OV. (H) The correlation in SKCM. The optimal cutoff of ARPC5 expression were used to divide patients into high- and low-expression groups.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: ARPC5 expression significantly correlated with OS based on Kaplan–Meier analysis. (A) The correlation in ESCA. (B) The correlation in HNSC. (C) The correlation in KIRC. (D) The correlation in KIRP. (E) The correlation in LIHC. (F) The correlation in LGG. (G) The correlation in OV. (H) The correlation in SKCM. The optimal cutoff of ARPC5 expression were used to divide patients into high- and low-expression groups.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing

    The correlation between ARPC5 expression and clinical stage, histologic grade, and tumor molecular subtypes in various cancers based on Spearman’s correlation analysis (the correlation with p < 0.05 were displayed). (A) The correlation between ARPC5 expression and clinical stage in pan-cancer. (B–C) The expression levels of ARPC5 in different clinical stages of KIRC (B) and KIRP (C) . (D) The correlation between ARPC2 expression and histologic grade in pan-cancer. (E–H) The expression levels of ARPC5 in different histologic grades of KIRC (E) , LGG (F) , LIHC (G) , and UCEC (H) . (I–R) The correlation between ARPC5 expression and molecular subtypes in ACC (I) , BRCA (J) , LGG (K) , HNSC (L) , KIRP (M) , OV (N) , LUSC (O) , PCPG (P) , STAD (Q) , UCEC (R) . rho; rank coefficient of Spearman. Pv; p -value. NS, no significance.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: The correlation between ARPC5 expression and clinical stage, histologic grade, and tumor molecular subtypes in various cancers based on Spearman’s correlation analysis (the correlation with p < 0.05 were displayed). (A) The correlation between ARPC5 expression and clinical stage in pan-cancer. (B–C) The expression levels of ARPC5 in different clinical stages of KIRC (B) and KIRP (C) . (D) The correlation between ARPC2 expression and histologic grade in pan-cancer. (E–H) The expression levels of ARPC5 in different histologic grades of KIRC (E) , LGG (F) , LIHC (G) , and UCEC (H) . (I–R) The correlation between ARPC5 expression and molecular subtypes in ACC (I) , BRCA (J) , LGG (K) , HNSC (L) , KIRP (M) , OV (N) , LUSC (O) , PCPG (P) , STAD (Q) , UCEC (R) . rho; rank coefficient of Spearman. Pv; p -value. NS, no significance.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing

    The correlation between ARPC5 expression and immune scores and stromal scores of tumor microenvironments in pan-cancer.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: The correlation between ARPC5 expression and immune scores and stromal scores of tumor microenvironments in pan-cancer.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing

    The correlation between ARPC5 and immune infiltration cells in pan-cancer based on TIMER algorithm. (A) Heatmap displayed the correlation between ARPC5 expression and the proportions of B cell, CD4 + T cell, CD8 + T cell, neutrophil, macrophage, and DC cell. (B) The top five cancer types (including KIRC, LGG, PRAD, THCA, and THYM) with most significant correlation between ARPC5 and immune infiltration cells were displayed with scatterplots. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: The correlation between ARPC5 and immune infiltration cells in pan-cancer based on TIMER algorithm. (A) Heatmap displayed the correlation between ARPC5 expression and the proportions of B cell, CD4 + T cell, CD8 + T cell, neutrophil, macrophage, and DC cell. (B) The top five cancer types (including KIRC, LGG, PRAD, THCA, and THYM) with most significant correlation between ARPC5 and immune infiltration cells were displayed with scatterplots. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing

    The correlation between ARPC5 expression and immune subtypes in pan-cancer using TISIDB. The cancers with significant correlation were displayed. (A) In BLCA. (B) In BRCA. (C) In CESC. (D) In KICH. (E) In KIRC. (F) In LGG. (G) In LIHC. (H) In LUAD. (I) In PAAD. (J) In OV. (K) PCPG. (L) PRAD. (M) In READ. ( N) In SARC. (O) In SKCM. (P) In STAD. (Q) In TGCT. (R) In THCA. (S) In UCS. (T) In UCEC. Pv; p -value. C1, wound healing; C2, IFN-gamma dominant; C3, inflammatory; C4, lymphocyte depleted; C5, immunologically quiet; C6, TGF-b dominant.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: The correlation between ARPC5 expression and immune subtypes in pan-cancer using TISIDB. The cancers with significant correlation were displayed. (A) In BLCA. (B) In BRCA. (C) In CESC. (D) In KICH. (E) In KIRC. (F) In LGG. (G) In LIHC. (H) In LUAD. (I) In PAAD. (J) In OV. (K) PCPG. (L) PRAD. (M) In READ. ( N) In SARC. (O) In SKCM. (P) In STAD. (Q) In TGCT. (R) In THCA. (S) In UCS. (T) In UCEC. Pv; p -value. C1, wound healing; C2, IFN-gamma dominant; C3, inflammatory; C4, lymphocyte depleted; C5, immunologically quiet; C6, TGF-b dominant.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing

    The relationship between ARPC5 and immune-checkmate inhibitors biomarkers in pan-cancer. (A) The heatmap showing the co-expression relationship between ARPC5 and 47 immune checkpoint–related genes. (B) Radar plot showing the relationship between ARPC5 and tumor mutation burden (TMB). (C) Radar plot showing the correlation of ARPC5 with microsatellite instability (MSI). (D) Radar plot showing the correlation of ARPC5 with neoantigens. The number in radar plot represents Spearman’s correlation coefficient. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: The relationship between ARPC5 and immune-checkmate inhibitors biomarkers in pan-cancer. (A) The heatmap showing the co-expression relationship between ARPC5 and 47 immune checkpoint–related genes. (B) Radar plot showing the relationship between ARPC5 and tumor mutation burden (TMB). (C) Radar plot showing the correlation of ARPC5 with microsatellite instability (MSI). (D) Radar plot showing the correlation of ARPC5 with neoantigens. The number in radar plot represents Spearman’s correlation coefficient. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing, Mutagenesis, Immunopeptidomics

    Correlation analysis between ARPC5 expression and RNA modification-related genes, DNA methyltransferases, and tumor stemness score in 33 cancer types. (A) Co-expression of ARPC5 with m1A-related genes. (B) Co-expression of ARPC5 with m5C-related genes. (C) Co-expression of ARPC5 with m6A-related genes. (D) Co-expression of ARPC5 with DNA methyltransferases. (E) The correlation between ARPC5 expression and Tumor Stemness score (DNAss). (F) The correlation between ARPC5 expression and Tumor Stemness score (RNAss). * p < 0.05; ** p < 0.01; *** p < 0.001.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: Correlation analysis between ARPC5 expression and RNA modification-related genes, DNA methyltransferases, and tumor stemness score in 33 cancer types. (A) Co-expression of ARPC5 with m1A-related genes. (B) Co-expression of ARPC5 with m5C-related genes. (C) Co-expression of ARPC5 with m6A-related genes. (D) Co-expression of ARPC5 with DNA methyltransferases. (E) The correlation between ARPC5 expression and Tumor Stemness score (DNAss). (F) The correlation between ARPC5 expression and Tumor Stemness score (RNAss). * p < 0.05; ** p < 0.01; *** p < 0.001.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing, RNA modification

    ARPC5 is upregulated in HCC cells and primary HCC tissues. (A) qPCR analysis of ARPC5 mRNA expression in four HCC cell lines (MHCC97-H, Huh7, HCC-LM3, and HepG2) and normal liver cell line (LO2). GAPDH was used as an internal control error bars represent M ± SEM (triplicate experiments). (B, C) The protein expression of ARPC5 was detected in four HCC cell lines and normal liver cell line with Western blot analysis. Error bars represent M ± SD of triplicate measurements. (D) The mRNA expression of ARPC5 in 40 pairs HCC tissues and adjacent para-carcinoma tissues was evaluated using qPCR. (E) Western blot analysis of ARPC5 protein expression in 10 paired HCC tissues and adjacent normal tissues. The number presented the relative protein expression levels of ARPC5. (F) Representative images of ARPC5 immunohistochemical staining analysis in the HCC tissue and adjacent normal liver tissue, original magnifications: ×40 and ×200. Scale bars, 50 μm. (G) Quantitative analysis of ARPC5 expression in HCC tissues based on mean optical density of immunohistochemical staining. Error bars represent the M ± SD of multiple tissues. (H) Kaplan–Meier curves showed that higher expression of ARPC5 was associated with poor DFS in HCC patients. * p < 0.05; ** p < 0.01; *** p < 0.001. ns, no significance.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: ARPC5 is upregulated in HCC cells and primary HCC tissues. (A) qPCR analysis of ARPC5 mRNA expression in four HCC cell lines (MHCC97-H, Huh7, HCC-LM3, and HepG2) and normal liver cell line (LO2). GAPDH was used as an internal control error bars represent M ± SEM (triplicate experiments). (B, C) The protein expression of ARPC5 was detected in four HCC cell lines and normal liver cell line with Western blot analysis. Error bars represent M ± SD of triplicate measurements. (D) The mRNA expression of ARPC5 in 40 pairs HCC tissues and adjacent para-carcinoma tissues was evaluated using qPCR. (E) Western blot analysis of ARPC5 protein expression in 10 paired HCC tissues and adjacent normal tissues. The number presented the relative protein expression levels of ARPC5. (F) Representative images of ARPC5 immunohistochemical staining analysis in the HCC tissue and adjacent normal liver tissue, original magnifications: ×40 and ×200. Scale bars, 50 μm. (G) Quantitative analysis of ARPC5 expression in HCC tissues based on mean optical density of immunohistochemical staining. Error bars represent the M ± SD of multiple tissues. (H) Kaplan–Meier curves showed that higher expression of ARPC5 was associated with poor DFS in HCC patients. * p < 0.05; ** p < 0.01; *** p < 0.001. ns, no significance.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing, Control, Western Blot, Immunohistochemical staining, Staining

    Silencing of ARPC5 inhibits cell proliferation and promotes cell apoptosis of HCC. (A) The knockdown efficiency of siRNA–ARPC5 was examined in HCC-LM3 and MHCC97-H cells with qPCR. (B) The knockdown efficiency of siRNA-ARPC5 was examined in HCC-LM3 and MHCC97-H cells with Western blot. The number presented as relative protein expression levels of ARPC5. ( C–D ) EdU assays for HCC-LM3 and MHCC 97-H were performed to evaluate cell proliferation ability after transfecting siRNA-ARPC5#1. Representative images (C) and the number of proliferative cells were calculated (D) ; original magnification, ×200. (E–F) Cellular growth curves were evaluated by CCK-8 assays in HCC-LM3 and MHCC97-H cells. (G – H) Flow cytometry was applied to test the apoptosis of HCC cells transfected with si-ARPC5 #1 in HCC-LM3 and MHCC 97-H cells. All data are presented as the M ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001. ns, no significance.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: Silencing of ARPC5 inhibits cell proliferation and promotes cell apoptosis of HCC. (A) The knockdown efficiency of siRNA–ARPC5 was examined in HCC-LM3 and MHCC97-H cells with qPCR. (B) The knockdown efficiency of siRNA-ARPC5 was examined in HCC-LM3 and MHCC97-H cells with Western blot. The number presented as relative protein expression levels of ARPC5. ( C–D ) EdU assays for HCC-LM3 and MHCC 97-H were performed to evaluate cell proliferation ability after transfecting siRNA-ARPC5#1. Representative images (C) and the number of proliferative cells were calculated (D) ; original magnification, ×200. (E–F) Cellular growth curves were evaluated by CCK-8 assays in HCC-LM3 and MHCC97-H cells. (G – H) Flow cytometry was applied to test the apoptosis of HCC cells transfected with si-ARPC5 #1 in HCC-LM3 and MHCC 97-H cells. All data are presented as the M ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001. ns, no significance.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Knockdown, Western Blot, Expressing, CCK-8 Assay, Flow Cytometry, Transfection

    Role of ARPC5 inhibition on migration, invasion, and epithelial–mesenchymal transition (EMT) of HCC cells. (A–D) Migration ability was assessed by scratch wound healing assay, representative images (A, B) were shown (original magnification, ×200; scale bars, 50 µm), and wound healing areas were calculated (C, D) . (E , F) Transwell assay was applied to examine the invasion ability, representative images (F) were shown (original magnification, ×200; scale bars, 50 µm), and the histogram showed the number of invasion cells (E) . (G) Western blot showed the changes of EMT proteins in HCC-LM3 and MHCC97-H cells transfected with si-ARPC5#1. *p < 0.05; **p < 0.01; ***p < 0.001.

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet: Role of ARPC5 inhibition on migration, invasion, and epithelial–mesenchymal transition (EMT) of HCC cells. (A–D) Migration ability was assessed by scratch wound healing assay, representative images (A, B) were shown (original magnification, ×200; scale bars, 50 µm), and wound healing areas were calculated (C, D) . (E , F) Transwell assay was applied to examine the invasion ability, representative images (F) were shown (original magnification, ×200; scale bars, 50 µm), and the histogram showed the number of invasion cells (E) . (G) Western blot showed the changes of EMT proteins in HCC-LM3 and MHCC97-H cells transfected with si-ARPC5#1. *p < 0.05; **p < 0.01; ***p < 0.001.

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Inhibition, Migration, Wound Healing Assay, Transwell Assay, Western Blot, Transfection

    Journal: Frontiers in Immunology

    Article Title: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma

    doi: 10.3389/fimmu.2022.944898

    Figure Lengend Snippet:

    Article Snippet: Afterward, mRNA expression of ARPC5 in different tissues, cell lines, and single-cell types were directly obtained from the Human Protein Atlas website ( https://www.proteinatlas.org/ ).

    Techniques: Expressing, Mutagenesis, Real-time Polymerase Chain Reaction, Small Interfering RNA